RESUMEN
Filamentous fungi are intensively used for producing industrial enzymes, including lignocellulases. Employing insoluble cellulose to induce the production of lignocellulases causes some drawbacks, e.g., a complex fermentation operation, which can be overcome by using soluble inducers such as cellobiose. Here, a triple ß-glucosidase mutant of Neurospora crassa, which prevents rapid turnover of cellobiose and thus allows the disaccharide to induce lignocellulases, was applied to profile the proteome responses to cellobiose and cellulose (Avicel). Our results revealed a shared proteomic response to cellobiose and Avicel, whose elements included lignocellulases and cellulolytic product transporters. While the cellulolytic proteins showed a correlated increase in protein and mRNA levels, only a moderate correlation was observed on a proteomic scale between protein and mRNA levels (R2 = 0.31). Ribosome biogenesis and rRNA processing were significantly overrepresented in the protein set with increased protein but unchanged mRNA abundances in response to Avicel. Ribosome biogenesis, as well as protein processing and protein export, was also enriched in the protein set that showed increased abundance in response to cellobiose. NCU05895, a homolog of yeast CWH43, is potentially involved in transferring a glycosylphosphatidylinositol (GPI) anchor to nascent proteins. This protein showed increased abundance but no significant change in mRNA levels. Disruption of CWH43 resulted in a significant decrease in cellulase activities and secreted protein levels in cultures grown on Avicel, suggesting a positive regulatory role for CWH43 in cellulase production. The findings should have an impact on a systems engineering approach for strain improvement for the production of lignocellulases.IMPORTANCE Lignocellulases are important industrial enzymes for sustainable production of biofuels and bio-products. Insoluble cellulose has been commonly used to induce the production of lignocellulases in filamentous fungi, which causes a difficult fermentation operation and enzyme loss due to adsorption to cellulose. The disadvantages can be overcome by using soluble inducers, such as the disaccharide cellobiose. Quantitative proteome profiling of the model filamentous fungus Neurospora crassa revealed cellobiose-dependent pathways for cellulase production, including protein processing and export. A protein (CWH43) potentially involved in protein processing was found to be a positive regulator of lignocellulase production. The cellobiose-dependent mechanisms provide new opportunities to improve the production of lignocellulases in filamentous fungi.
Asunto(s)
Celobiosa/metabolismo , Proteínas Fúngicas/metabolismo , Neurospora crassa/metabolismo , Proteoma/metabolismo , beta-Glucosidasa/genética , Biocombustibles/microbiología , Celulosa/metabolismo , Proteínas Fúngicas/genética , Neurospora crassa/enzimología , Neurospora crassa/genética , Proteoma/genética , beta-Glucosidasa/deficienciaRESUMEN
It is inevitably for cellobiose to be co-generated during enzymatic hydrolysis of cellulose, especially when the cellulase is lack of ß-glucosidase activity. In the present study, cellobiose was found superior to glucose for cell growth by L. starkeyi, regardless of the sugar concentrations. Glucose was assimilated preferentially when cellobiose and glucose were co-fermented. Deficiency of ß-glucosidase was observed to be beneficial for the simultaneous saccharification and lipid production (SSLP). High lipid titer and cellulose conversion of 9.1 g/L and 92.4%, respectively, were achieved when cellulase with low ß-glucosidase activity was supplemented. The SSLP achieved higher lipid titer of 9.5 g/L when a pre-hydrolysis process was introduced. The glucosidase generated by L. starkeyi was primarily cell-bound, which contributed significantly to the cellobiose utilization and the high lipid production. These results provided a novel scheme for enhanced lipid production from lignocellulosic biomass with reduced enzyme usage, which is believed to facilitate the design of a more cost-effective lignocellulose-to-lipid route.
Asunto(s)
Lípidos/biosíntesis , Lipomyces/metabolismo , beta-Glucosidasa/deficiencia , Biomasa , Celobiosa/metabolismo , Fermentación , Glucosa/metabolismo , Hidrólisis , Lipomyces/crecimiento & desarrollo , beta-Glucosidasa/metabolismoRESUMEN
ß-glucosidases [GBA1 (glucocerebrosidase) and GBA2] are ubiquitous essential enzymes. Lysosomal GBA1 and cytosol-facing GBA2 degrade glucosylceramide (GlcCer); GBA1 deficiency causes Gaucher disease, a lysosomal storage disorder characterized by lysosomal accumulation of GlcCer, which is partly converted to glucosylsphingosine (GlcSph). GBA1 and GBA2 also may transfer glucose from GlcCer to cholesterol, yielding glucosylated cholesterol (GlcChol). Here, we aimed to clarify the role of zebrafish Gba2 in glycosphingolipid metabolism during Gba1 deficiency in zebrafish (Danio rerio), which are able to survive total Gba1 deficiency. We developed Gba1 (gba1-/-), Gba2 (gba2-/-), and double (gba1-/-:gba2-/-) zebrafish knockouts using CRISPR/Cas9 and explored the effects of both genetic and pharmacological interventions on GlcCer metabolism in individual larvae. Activity-based probes and quantification of relevant glycolipid metabolites confirmed enzyme deficiency. GlcSph increased in gba1-/- larvae (0.09 pmol/fish) but did not increase more in gba1-/-:gba2-/- larvae. GlcCer was comparable in gba1-/- and WT larvae but increased in gba2-/- and gba1-/-:gba2-/- larvae. Independent of Gba1 status, GlcChol was low in all gba2-/- larvae (0.05 vs. 0.18 pmol/fish in WT). Pharmacologic inactivation of zebrafish Gba1 comparably increased GlcSph. Inhibition of GlcCer synthase (GCS) in Gba1-deficient larvae reduced GlcCer and GlcSph, and concomitant inhibition of GCS and Gba2 with iminosugars also reduced excessive GlcChol. Finally, overexpression of human GBA1 and injection of recombinant GBA1 both decreased GlcSph. We determined that zebrafish larvae offer an attractive model to study glucosidase actions in glycosphingolipid metabolism in vivo, and we identified distinguishing characteristics of zebrafish Gba2 deficiency.
Asunto(s)
Glucosilceramidasa/deficiencia , Glicoesfingolípidos/metabolismo , Modelos Biológicos , Proteínas de Pez Cebra/deficiencia , Proteínas de Pez Cebra/metabolismo , beta-Glucosidasa/metabolismo , Animales , Células Cultivadas , Glucosilceramidasa/metabolismo , Pez Cebra , beta-Glucosidasa/deficienciaRESUMEN
Heterozygous mutations in GBA1, the gene which encodes the lysosomal enzyme glucocerebrosidase (GCase), are a strong genetic risk factor for the development of Lewy body dementia (LBD). Until this point however, recapitulation of the symptoms and pathology of LBD has been limited to a homozygous GBA1 mouse model which genetically and enzymatically reflects the lysosomal storage disorder Gaucher's disease. This study reports for the first time cognitive impairment by two independent behavioural tests in heterozygous GBA1 mutant mice (D409V/WT) which demonstrate significant cognitive impairment by the age of 12 months. Furthermore, reductions in GBA1 GCase enzyme activity within the brain reflects levels seen in sporadic and GBA1 mutant LBD patients. While there is no overt deposition of Lewy bodies within the hippocampus, alterations to cholinergic machinery and glial proliferation are evident, both pathological features of LBD. Interestingly, we also describe the novel finding of significantly reduced GBA2 GCase enzyme activity specifically within the hippocampus. This suggests that reduced GBA1 GCase enzyme activity dis-equilibrates the finely balanced glycosphingolipid metabolism pathway and that reductions in GBA2 GCase enzyme could contribute to the pathological and behavioural effects seen. Overall, this study presents evidence to suggest that pathological hallmarks associated with LBD specifically affecting brain regions intrinsically linked with cognition are present in the D409V/WT mice. In the absence of Lewy body deposition, the D409V/WT mice could be considered an early pre-clinical model of LBD with potential for drug discovery. Since few robust pre-clinical models of LBD currently exist, with further characterization, the mouse model described here may contribute significantly to developments in the LBD field.
Asunto(s)
Trastornos del Conocimiento/genética , Modelos Animales de Enfermedad , Glucosilceramidasa/genética , Hipocampo/enzimología , Enfermedad por Cuerpos de Lewy/enzimología , Animales , Corteza Cerebral/enzimología , Conducta Exploratoria , Gliosis/genética , Gliosis/patología , Glucosilceramidasa/deficiencia , Glucosilceramidas/metabolismo , Glicoesfingolípidos/metabolismo , Heterocigoto , Hipocampo/patología , Lisosomas/enzimología , Masculino , Aprendizaje por Laberinto , Ratones , Ratones Endogámicos C57BL , Mutación Missense , Prueba de Desempeño de Rotación con Aceleración Constante , Proteínas de Transporte Vesicular de Acetilcolina/análisis , beta-Glucosidasa/deficienciaRESUMEN
The nonlysosomal glucosylceramidase ß2 (GBA2) catalyzes the hydrolysis of glucosylceramide to glucose and ceramide. Mutations in the human GBA2 gene have been associated with hereditary spastic paraplegia (HSP), autosomal-recessive cerebellar ataxia (ARCA), and the Marinesco-Sjögren-like syndrome. However, the underlying molecular mechanisms are ill-defined. Here, using biochemistry, immunohistochemistry, structural modeling, and mouse genetics, we demonstrate that all but one of the spastic gait locus #46 (SPG46)-connected mutations cause a loss of GBA2 activity. We demonstrate that GBA2 proteins form oligomeric complexes and that protein-protein interactions are perturbed by some of these mutations. To study the pathogenesis of GBA2-related HSP and ARCA in vivo, we investigated GBA2-KO mice as a mammalian model system. However, these mice exhibited a high phenotypic variance and did not fully resemble the human phenotype, suggesting that mouse and human GBA2 differ in function. Whereas some GBA2-KO mice displayed a strong locomotor defect, others displayed only mild alterations of the gait pattern and no signs of cerebellar defects. On a cellular level, inhibition of GBA2 activity in isolated cerebellar neurons dramatically affected F-actin dynamics and reduced neurite outgrowth, which has been associated with the development of neurological disorders. Our results shed light on the molecular mechanism underlying the pathogenesis of GBA2-related HSP and ARCA and reveal species-specific differences in GBA2 function in vivo.
Asunto(s)
Ataxia Cerebelosa/metabolismo , Locomoción/genética , Mutación con Pérdida de Función , Paraplejía Espástica Hereditaria/metabolismo , beta-Glucosidasa/metabolismo , Animales , Biocatálisis , Ataxia Cerebelosa/genética , Glucosilceramidasa , Humanos , Ratones , Ratones Noqueados , Paraplejía Espástica Hereditaria/genética , Especificidad de la Especie , beta-Glucosidasa/antagonistas & inhibidores , beta-Glucosidasa/deficiencia , beta-Glucosidasa/genéticaRESUMEN
Mutations in GBA1 encountered in Gaucher disease are a leading risk factor for Parkinson disease and associated Lewy body disorders. Many GBA1 mutation carriers, especially those with severe or null GBA1 alleles, have earlier and more progressive parkinsonism. To model the effect of partial glucocerebrosidase deficiency on neurological progression in vivo, mice with a human A53T α-synuclein (SNCAA53T) transgene were crossed with heterozygous null gba mice (gba+/-). Survival analysis of 84 mice showed that in gba+/-//SNCAA53T hemizygotes and homozygotes, the symptom onset was significantly earlier than in gba+/+//SNCAA53T mice (p-values 0.023-0.0030), with exacerbated disease progression (p-value <0.0001). Over-expression of SNCAA53T had no effect on glucocerebrosidase levels or activity. Immunoblotting demonstrated that gba haploinsufficiency did not lead to increased levels of either monomeric SNCA or insoluble high molecular weight SNCA in this model. Immunohistochemical analyses demonstrated that the abundance and distribution of SNCA pathology was also unaltered by gba haploinsufficiency. Thus, while the underlying mechanism is not clear, this model shows that gba deficiency impacts the age of onset and disease duration in aged SNCAA53T mice, providing a valuable resource to identify modifiers, pathways and possible moonlighting roles of glucocerebrosidase in Parkinson pathogenesis.
Asunto(s)
Enfermedad de Gaucher/genética , Glucosilceramidasa/genética , Haploinsuficiencia , Enfermedad de Parkinson/genética , alfa-Sinucleína/genética , Edad de Inicio , Animales , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Femenino , Enfermedad de Gaucher/complicaciones , Glucosilceramidasa/deficiencia , Glucosilceramidas/análisis , Heterocigoto , Humanos , Masculino , Ratones , Ratones Noqueados , Ratones Transgénicos , Mutación , Enfermedad de Parkinson/etiología , Psicosina/análogos & derivados , Psicosina/análisis , Transgenes , alfa-Sinucleína/análisis , alfa-Sinucleína/deficiencia , alfa-Sinucleína/metabolismo , beta-Glucosidasa/deficiencia , beta-Glucosidasa/genéticaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Gaucher/complicaciones , Enfermedad de Gaucher/genética , Enfermedad de Gaucher/patología , Biomarcadores de Tumor/análisis , Espectrometría de Fluorescencia , beta-Glucosidasa/análisis , beta-Glucosidasa/deficiencia , Esplenomegalia/complicaciones , Esplenomegalia/diagnóstico , Sistema Nervioso Central/patología , Trastornos Hemorrágicos/complicaciones , Densitometría/métodosRESUMEN
Gaucher disease (GD) is the most common lysosomal disorder resulting from deficient activity of the ß-glucosidase enzyme that causes accumulation of glucosylceramide in the macrophage-monocyte system. Notably, because of non-specific symptoms and a lack of awareness, patients with GD experience long diagnostic delays. The aim of this study was to apply a diagnostic algorithm to identify GD type 1 among adults subjects referred to Italian haematology outpatient units because of splenomegaly and/or thrombocytopenia and, eventually, to estimate the prevalence of GD in this selected population. One hundred and ninety-six subjects (61 females, 135 males; mean age 47.8 ± 18.2 years) have been enrolled in the study and tested for ß-glucosidase enzyme activity on dried blood spot (DBS). Seven of 196 patients have been diagnosed with GD, (5 females and 2 males) with mean age 31.8 ± 8.2 years, with a prevalence of 3.6% (with a prevalence of 3.6% (I95% CI 1.4-7.2; 1/28 patients) in this population. These results show that the use of an appropriate diagnostic algorithm and a simple diagnostic method, such as DBS, are important tools to facilitate the diagnosis of a rare disease even for not disease-expert physicians.
Asunto(s)
Algoritmos , Enfermedad de Gaucher/diagnóstico , Esplenomegalia/diagnóstico , Trombocitopenia/diagnóstico , beta-Glucosidasa/sangre , Adulto , Anciano , Pruebas con Sangre Seca , Diagnóstico Precoz , Femenino , Enfermedad de Gaucher/sangre , Enfermedad de Gaucher/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Esplenomegalia/sangre , Esplenomegalia/complicaciones , Trombocitopenia/sangre , Trombocitopenia/complicaciones , beta-Glucosidasa/deficienciaRESUMEN
Glucosylceramide is a membrane glycolipid made up of the sphingolipid ceramide and glucose, and has a wide intracellular distribution. Glucosylceramide is degraded to ceramide and glucose by distinct, non-homologous enzymes, including glucocerebrosidase (GBA), localized in the endolysosomal pathway, and ß-glucosidase 2 (GBA2), which is associated with the plasma membrane and/or the endoplasmic reticulum. It is well established that mutations in the GBA gene result in endolysosomal glucosylceramide accumulation, which triggers Gaucher disease. In contrast, the biological significance of GBA2 is less well understood. GBA2-deficient mice present with male infertility, but humans carrying mutations in the GBA2 gene are affected with a combination of cerebellar ataxia and spastic paraplegia, as well as with thin corpus callosum and cognitive impairment (SPastic Gait locus #46, SPG46). To improve our understanding of the biochemical consequences of the GBA2 mutations, we have evaluated five nonsense and five missense GBA2 mutants for their enzyme activity. In transfected cells, the mutant forms of GBA2 were present in widely different amounts, ranging from overabundant to very minor, compared to the wild type enzyme. Nevertheless, none of the GBA2 mutant cDNAs raised the enzyme activity in transfected cells, in contrast to the wild-type enzyme. These results suggest that SPG46 patients have a severe deficit in GBA2 activity, because the GBA2 mutants are intrinsically inactive and/or reduced in amount. This assessment of the expression levels and enzyme activities of mutant forms of GBA2 offers a first insight in the biochemical basis of the complex pathologies seen in SPG46.
Asunto(s)
Ataxia Cerebelosa/genética , Mutación , Paraplejía Espástica Hereditaria/genética , beta-Glucosidasa/genética , Animales , Células COS , Línea Celular Tumoral , Ataxia Cerebelosa/enzimología , Ataxia Cerebelosa/patología , Retículo Endoplásmico/enzimología , Retículo Endoplásmico/patología , Pruebas de Enzimas , Regulación de la Expresión Génica , Glucosilceramidasa , Células HeLa , Humanos , Lisosomas/enzimología , Lisosomas/patología , Neuronas/enzimología , Neuronas/patología , Plásmidos/química , Plásmidos/metabolismo , Transducción de Señal , Paraplejía Espástica Hereditaria/enzimología , Paraplejía Espástica Hereditaria/patología , Transfección , Transgenes , beta-Glucosidasa/deficienciaRESUMEN
Beta-glucosidases (GBA) include GBA1, GBA2 and other ß-glucosidases (non-GBA1-2). GBA1 is a lysosomal and GBA2 an extra-lysosomal enzyme. GBA1- and GBA2-deficient genetic conditions, with different phenotypes, are glucosylceramide (GC; the main GBA substrate) accumulating diseases. To study the activity profile of GBA, live fibroblasts were loaded with radioactive GC. The GC metabolism was measured in wild-type, GBA1-deficient (Gaucher disease) and GBA2-deficient (Gba2(-/- )mouse) cells. The differences found allowed the prediction of marked proportions of GBA1, GBA2, and particularly non-GBA1-2 (probably including GBA3, a cytosolic ß-glucosidase) activity for wild-type cells. The high proportion of non-GBA1-2 suggests an important role of these enzymes.
Asunto(s)
Fibroblastos/enzimología , Fibroblastos/metabolismo , beta-Glucosidasa/metabolismo , Animales , Niño , Preescolar , Activación Enzimática , Fibroblastos/patología , Humanos , Recién Nacido , Ratones , beta-Glucosidasa/deficiencia , beta-Glucosidasa/genéticaRESUMEN
Taliglucerase alfa is a ß-glucosidase enzyme replacement therapy (ERT) approved in the US and other countries for the treatment of Gaucher disease (GD) in adults and is approved in pediatric and adult patients in Australia and Canada. It is the first approved plant cell-expressed recombinant human protein. A Phase 3, multicenter, open-label, 9-month study assessed safety and efficacy of switching to taliglucerase alfa in adult and pediatric patients with GD treated with imiglucerase for at least the previous 2years. Patients with stable disease were offered taliglucerase alfa treatment using the same dose (9-60U/kg body weight) and regimen of administration (every 2weeks) as imiglucerase. This report summarizes results from 26 adult and 5 pediatric patients who participated in the trial. Disease parameters (spleen and liver volumes, hemoglobin concentration, platelet count, and biomarker levels) remained stable through 9months of treatment in adults and children following the switch from imiglucerase. All treatment-related adverse events were mild or moderate in severity and transient in nature. Exploratory parameters of linear growth and development showed positive outcomes in pediatric patients. These findings provide evidence of the efficacy and safety profile of taliglucerase alfa as an ERT for GD in patients previously treated with imiglucerase. This trial was registered at www.clinicaltrials.gov as # NCT00712348.
Asunto(s)
Sustitución de Medicamentos , Enfermedad de Gaucher/tratamiento farmacológico , Glucosilceramidasa/uso terapéutico , beta-Glucosidasa/deficiencia , Adolescente , Adulto , Anciano , Plaquetas/efectos de los fármacos , Niño , Terapia de Reemplazo Enzimático , Enfermedad de Gaucher/enzimología , Enfermedad de Gaucher/genética , Enfermedad de Gaucher/patología , Expresión Génica , Glucosilceramidasa/biosíntesis , Hemoglobinas/metabolismo , Humanos , Hígado/efectos de los fármacos , Hígado/enzimología , Hígado/patología , Masculino , Recuento de Plaquetas , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/uso terapéutico , Bazo/efectos de los fármacos , Bazo/enzimología , Bazo/patología , Adulto Joven , beta-Glucosidasa/genéticaRESUMEN
Direct cellobiose production from cellulose by a genetically modified fungus-Neurospora crassa, was explored in this study. A library of N. crassa sextuple beta-glucosidase (bgl) gene deletion strains was constructed. Various concentrations of cellobiose were detected in the culture broth of the N. crassa sextuple beta-glucosidase (bgl) gene deletion strains when grown on Avicel without exogenous cellulase addition. The sextuple bgl deletion strains expressing one of the three basally transcribed bgl genes are the best cellobiose producers. For most sextuple strains, the multiple bgl gene deletion has no negative effect on the production of other cellulases. The induction of major endoglucanases and exoglucanases on Avicel in most of the sextuple bgl deletions strains was as fast as or faster than that of the wild type, except for strain F4. The best cellobiose producing strain, F5, produced 7.7 g/L of cellobiose from 20 g/L of Avicel in four days and utilized the Avicel as fast as did the wild type (even in the presence of high cellobiose concentration). The cellobiose yield from cellulose was about 48.3%.
Asunto(s)
Celobiosa/biosíntesis , Celulosa/metabolismo , Proteínas Fúngicas/metabolismo , Neurospora crassa/enzimología , beta-Glucosidasa/metabolismo , Celulasa/metabolismo , Cruzamientos Genéticos , Inducción Enzimática , Proteínas Fúngicas/genética , Eliminación de Gen , Genes Fúngicos , Neurospora crassa/genética , ARN de Hongos/genética , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Especificidad de la Especie , beta-Glucosidasa/deficiencia , beta-Glucosidasa/genéticaRESUMEN
Lysosomal glucocerebrosidase (GBA1) deficiency is causative for Gaucher disease. Not all individuals with GBA1 mutations develop neurological involvement raising the possibility that other factors may provide compensatory protection. One factor may be the activity of the non-lysosomal ß-glucosidase (GBA2) which exhibits catalytic activity towards glucosylceramide and is reported to be highly expressed in brain tissue. Here, we assessed brain GBA2 enzymatic activity in wild type, heterozygote and GBA1 deficient mice. Additionally, we determined activity in leucocytes obtained from 13 patients with Gaucher disease, 10 patients with enzymology consistent with heterozygote status and 19 controls. For wild type animals, GBA2 accounted for over 85 % of total brain GBA activity and was significantly elevated in GBA1 deficient mice when compared to heterozygote and wild types (GBA1 deficient; 92.4 ± 5.6, heterozygote; 71.5 ± 2.4, wild type 76.8 ± 5.1 nmol/h/mg protein). For the patient samples, five Gaucher patients had GBA2 leucocyte activities markedly greater than controls. No difference in GBA2 activity was apparent between the control and carrier groups. Undetectable GBA2 activity was identified in four leucocyte preparations; one in the control group, two in the carrier group and one from the Gaucher disease group. Work is now required to ascertain whether GBA2 activity is a disease modifying factor in Gaucher disease and to identify the mechanism(s) responsible for triggering increased GBA2 activity in GBA1 deficiency states.
Asunto(s)
Encéfalo/enzimología , Encéfalo/metabolismo , Enfermedad de Gaucher/enzimología , Enfermedad de Gaucher/metabolismo , Glucosilceramidasa/metabolismo , Leucocitos/enzimología , beta-Glucosidasa/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Niño , Preescolar , Femenino , Enfermedad de Gaucher/sangre , Enfermedad de Gaucher/genética , Glucosilceramidasa/deficiencia , Glucosilceramidasa/genética , Glucosilceramidas/metabolismo , Heterocigoto , Humanos , Lactante , Leucocitos/metabolismo , Masculino , Ratones , Persona de Mediana Edad , Mutación , Adulto Joven , beta-Glucosidasa/deficiencia , beta-Glucosidasa/metabolismoRESUMEN
BACKGROUND AND AIMS: Glycolipids have been shown to serve specialized functions in cell signalling, proliferation and differentiation processes, which are all important during liver regeneration. We previously generated beta-glucosidase 2 (GBA2) knockout mice that accumulate the glycolipid glucosylceramide in various tissues, including the liver. The present study addressed the role of GBA2-deficiency and subsequent glucosylceramide accumulation in liver regeneration. METHODS: Gba2 knockout and wild-type mice were subjected to two-third partial hepatectomy. Mice were sacrificed at different time points, blood was collected, and the remnant liver was removed. Glucosylceramide and ceramide were quantified using mass spectrometry from whole liver and isolated hepatocytes. Serum and hepatocytic supernatant of IL-6, TNF-α and TGF-ß levels were measured using ELISA. Cell signalling proteins were analysed using immunoblots. RESULTS: Regenerating liver after partial hepatectomy showed a significant increase of hepatic glucosylceramide in GBA2-deficient mice compared to controls. Accumulation of glucosylceramide was associated with a delay in liver regeneration and reduced serum levels of IL-6 and TNF-α. Furthermore, reduced IL-6 led to decreased expression of the phosphorylated form of the signal transducer and activator of transcription 3 (P-STAT3). CONCLUSIONS: We conclude that increased glucosylceramide affects cytokine- and growth factor-mediated signalling pathways during liver regeneration. Thus, the repression of IL-6/STAT3 signalling pathway seems to be one of the mechanisms for the delay of liver regeneration in GBA2-deficient mice.
Asunto(s)
Ceramidas/metabolismo , Glucosilceramidas/metabolismo , Hepatocitos/patología , Regeneración Hepática/fisiología , beta-Glucosidasa/deficiencia , Animales , Células Cultivadas , Ceramidas/análisis , Citocinas/sangre , Glucosilceramidas/análisis , Hepatectomía , Hepatocitos/metabolismo , Hígado/química , Hígado/metabolismo , Hígado/patología , Ratones , Ratones Noqueados , Fosforilación , Factor de Transcripción STAT3/metabolismo , beta-Glucosidasa/genéticaRESUMEN
Scholz's disease or metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by a deficiency in arylsulfatase A (ARSA: EC 3.1.6.8). This enzyme is responsible for the degradation of sulfatides commonly called cerebroside-3-sulfate or 3-O-sulfogalactosylcéramide in galactocérébroside and sulfate. The success of hydrolysis of these sphingolipids by ARSA necessarily depends on the presence of saposine B forms a complex with the substrate. The pathological accumulation of sulfatides in the nervous system (myelin, neurons and glial cells) results most often neurological, mental retardation, nervous disorders, blindness. The metachromatic granules accumulated in the central nervous system and peripheral compounds are highly toxic. These are at high levels in the urine of patients affected by the MLD. Arylsulfatase A activity is collapsed in these patients. Unfortunately, the value of enzyme activity is not a predictor of clinical severity of the neuropathology. In contrast, the study of the gene that codes for the ARSA is seen as a way to diagnose the simplest and most reliable of the disease to avoid misdiagnosis due to the presence of pseudodeficit. The conventional therapeutic approaches are essentially symptomatic. They were made in order to restore the enzyme activity of arylsulfatase A and prevent the progression of the pathological accumulation of sulfatides and consequently reduce morbidity associated with MLD.
Asunto(s)
Cerebrósido Sulfatasa/deficiencia , Leucodistrofia Metacromática/tratamiento farmacológico , Leucodistrofia Metacromática/enzimología , Anticoagulantes/uso terapéutico , Ceguera/etiología , Enfermedad de Gaucher/enzimología , Enfermedad de Gaucher/genética , Genotipo , Humanos , Hidrólisis , Discapacidad Intelectual/etiología , Leucodistrofia Metacromática/genética , Enfermedades del Sistema Nervioso/etiología , Fenotipo , Esfingolipidosis/genética , Esfingolípidos/metabolismo , Sulfoglicoesfingolípidos/metabolismo , Warfarina/uso terapéutico , beta-Glucosidasa/deficienciaRESUMEN
La enfermedad de Gaucher es una entidad hereditaria del metabolismo de los esfingolípidos con un patrón de herencia autosómico recesivo determinada por una deficiencia de la actividad de la enzima b-glucosidasa ácida. En este trabajo se presentan 2 pacientes en edad pediátrica, uno del sexo femenino y otro del masculino, ambos con anemia y hepatoesplenomegalia confirmadas por ultrasonido. El aspirado de médula ósea mostró infiltración por células de almacenamiento, niveles bajos de la actividad enzimática de b-glucocerebrosidasa y el diagnóstico molecular de las posibles mutaciones conocidas confirmaron la enfermedad en ambos pacientes que se encuentran en tratamiento con terapia enzimática sustitutiva (imiglucerasa), con evolución favorable en los aspectos clínicos y humorales(AU)
Gaucher's disease is a hereditary entity related to sphingolipids metabolism with an autosomal recessive hereditary pattern determined by a failure of the acid b-glucosidase enzyme. In present paper authors present the case of two pediatric patients (1 female and 1 male) both presenting with anemia and hepatosplenomegaly by ultrasound (US). Bone marrow aspirate showed infiltration by storage cells, low levels of enzymatic activity of b-glucocerebroside and a molecular diagnosis of potential known mutations confirmed the disease in both patients, who are under treatment with substitutive enzymatic therapy (imiglucerase) with a favorable course in clinical and humoral features(AU)
Asunto(s)
Humanos , Preescolar , Niño , Masculino , Femenino , Enfermedad de Gaucher/terapia , Enzimas/uso terapéutico , beta-Glucosidasa/deficienciaRESUMEN
La enfermedad de Gaucher es una entidad hereditaria del metabolismo de los esfingolípidos con un patrón de herencia autosómico recesivo determinada por una deficiencia de la actividad de la enzima b-glucosidasa ácida. En este trabajo se presentan 2 pacientes en edad pediátrica, uno del sexo femenino y otro del masculino, ambos con anemia y hepatoesplenomegalia confirmadas por ultrasonido. El aspirado de médula ósea mostró infiltración por células de almacenamiento, niveles bajos de la actividad enzimática de b-glucocerebrosidasa y el diagnóstico molecular de las posibles mutaciones conocidas confirmaron la enfermedad en ambos pacientes que se encuentran en tratamiento con terapia enzimática sustitutiva (imiglucerasa), con evolución favorable en los aspectos clínicos y humorales.
Gaucher's disease is a hereditary entity related to sphingolipids metabolism with an autosomal recessive hereditary pattern determined by a failure of the acid b-glucosidase enzyme. In present paper authors present the case of two pediatric patients (1 female and 1 male) both presenting with anemia and hepatosplenomegaly by ultrasound (US). Bone marrow aspirate showed infiltration by storage cells, low levels of enzymatic activity of b-glucocerebroside and a molecular diagnosis of potential known mutations confirmed the disease in both patients, who are under treatment with substitutive enzymatic therapy (imiglucerase) with a favorable course in clinical and humoral features.
Asunto(s)
Humanos , Masculino , Preescolar , Niño , Femenino , Enfermedad de Gaucher/terapia , Enzimas/uso terapéutico , beta-Glucosidasa/deficienciaRESUMEN
beta-Glucosidase 2 (GBA2) is a resident enzyme of the endoplasmic reticulum thought to play a role in the metabolism of bile acid-glucose conjugates. To gain insight into the biological function of this enzyme and its substrates, we generated mice deficient in GBA2 and found that these animals had normal bile acid metabolism. Knockout males exhibited impaired fertility. Microscopic examination of sperm revealed large round heads (globozoospermia), abnormal acrosomes, and defective mobility. Glycolipids, identified as glucosylceramides by mass spectrometry, accumulated in the testes, brains, and livers of the knockout mice but did not cause obvious neurological symptoms, organomegaly, or a reduction in lifespan. Recombinant GBA2 hydrolyzed glucosylceramide to glucose and ceramide; the same reaction catalyzed by the beta-glucosidase acid 1 (GBA1) defective in subjects with the Gaucher's form of lysosomal storage disease. We conclude that GBA2 is a glucosylceramidase whose loss causes accumulation of glycolipids and an endoplasmic reticulum storage disease.
Asunto(s)
Glucolípidos/metabolismo , Infertilidad Masculina/enzimología , Infertilidad Masculina/patología , Enfermedades Metabólicas/enzimología , Enfermedades Metabólicas/patología , beta-Glucosidasa/metabolismo , Animales , Ácidos y Sales Biliares/metabolismo , Fertilización In Vitro , Expresión Génica , Glicosilación , Infertilidad Masculina/genética , Masculino , Enfermedades Metabólicas/genética , Ratones , Ratones Noqueados , Mutación/genética , Especificidad de Órganos , Recuento de Espermatozoides , Motilidad Espermática , Testículo/enzimología , beta-Glucosidasa/deficiencia , beta-Glucosidasa/genéticaRESUMEN
BACKGROUND: Gaucher's disease (GD) is a disorder caused by the deficiency of lysosomal beta-glucosidase, an enzyme that participates in the degradation of glycosphingolipids. Deficiency of this enzyme results in the storage of glucocerebrosides in lysosomes of macrophage. No studies are available in the literature comparing biochemical and kinetic behavior of this enzyme in leukocytes and fibroblasts from normal individuals, obligate heterozygotes and patients with GD. METHODS: The behavior of beta-glu in terms of optimum pH, heat stability, Km and Vmax in leukocytes from patients with GD and obligated heterozygotes with different genotypes and normal individuals were characterized. RESULTS: Optimum pH was similar in all groups analyzed. In terms of Km and Vmax, several differences among heterozygotes and homozygotes groups and among these groups and normal enzyme were observed. Enzyme from all groups were inactivated when preincubated at 60 degrees C, but some enzymes were more stable than other. Results showed a different behavior of the enzyme in the 3 groups under analysis. Such behavior varied according to individual mutation. CONCLUSIONS: The catalytic gradient presented by beta-glu allowed the correlation of N370S mutation-which presented more stable biochemical properties-with the non-neurological clinical condition of the disease and the catalytically less stable mutation (D409H), with the neurological clinical condition of GD. This study contributes to a better understanding of the repercussion of the different mutations on the protein function, thus allowing to predict the severity of such complex metabolic disorder and to anticipate the most appropriate intervention for each case specifically.